Search database
Filter
125
Text search: туберкулёз
Featured
Language
Document type
77
24
9
6
3
3
1
1
1
Countries / Regions
6
3
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
26
14
5
5
5
5
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
Category
107
7
2
2
2
2
Toolboxes
89
6
6
5
5
3
1
Evidence to decision framework

Drug-Resistant tuberculosis

E.G. Brown Jr, D.S. Dooley, K. Smith Curry International Tuberculosis Center, State of California, California Health & Human Service Agency, Department of Public Health (2016) C1
A survival guide for clinicans. 3rd edition.
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
Поэтому уже давно возникала мысль о том,что подробный комментарий по вопросам научных знаний и практическогоопыта, лежащих в основе политики ВОЗ по борьбе ... more
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Version: 24 April 2018
The consolidated guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management, adapted to the national and local epidemiology of TB, the availability of resources, the health infrastructure and other national and local determinants. The gu ... more
Evidence-to-Decision and Grade tables
2nd edition. T The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or sympt ... more
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med ... more

Diagnostics Catalog August 2018

Global Drug Facility World Health Organization WHO, Stop TB (2018) C_WHO
Stop TB`s GDF provides a wide range of diagnostic equipment and laboratory supplies in its Diagnostics Catalog

Medicines Catalog August 2018

Global Drug Facility World Health Organization WHO, Stop TB (2018) C_WHO
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.

Field Guide for the Management of Drug-Resistant Tuberculosis

A. Piubello The International Union Against Tuberculosis and Lung Disease (2018)
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
2nd edition. The practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide
Guía para países de bajos ingresos. 2 edición
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ... more
The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci ... more